Skip to main content
HRMY logo

HRMY · Harmony Biosciences Holdings, Inc.

Track HRMY — free
$33.01 +0.05 (+0.15%) At close · Nov 17
Market Cap
$1.94B
Shares
58.72M
Volume · Nov 17 607.35K Avg daily vol (3M) 1M

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$33.01 Open$32.96 Day$32.46–33.13 52W close$26.54–42.86 Avg vol 30d1.1M Short int6.7M · 11.3% of shares · 5.6d Short vol46% Last earningsNov 4, 2026 DataAug 2020–Nov 2026 Filing10-Q · Nov 4

Up next

Feb 23, 2027 Est · unconfirmed · in 14 wks

Latest documents

2026
Nov 4
Earnings call
WACIX growth and BP-205 data support revenue outlook

Harmony Biosciences reported Q3 WACIX net revenue of $269 million and reiterated 2026 guidance of $1 to $1.04 billion. BP-205 showed an approximately 29-hour effective half-life, and Peter Anastasiou will become CEO on January 1, 2027.

4 source passages
For the third quarter of 2026, we reported net revenue of $269 million compared to $239 million in the prior year quarter. And we remain on track to achieve our full-year guidance of $1 to $1.04 billion. The mean effective half-life was approximately 29 hours, not meaningfully different from the SAD study, and it supports one steady dosing and the potential for durable efficacy throughout the day and potentially with no troublesome insomnia as evidenced by the tolerability profile of BP-205 from the SAD and the MAD data. I will be stepping down at the end of the year, and Peter Anastasiou, our Senior Executive Vice President and Chief Operating Officer, will succeed me as President and Chief Executive Officer, effective January 1, 2027. Open the document at this passage
Nov 4
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Net product revenue rose 12.3%; Pitolisant GR accepted for review

Harmony’s net product revenue increased $29.5 million, or 12.3%, for the three months ended September 30, 2026. Pitolisant GR received full FDA review with a target PDUFA date of April 1, 2027.

Revenue $268.92M ▲ 12.3% Net income $48.2M ▼ 5.2% Diluted EPS $0.81 ▼ 6.9%
Read from the MD&A section
3 source passages
At Harmony, we are cultivating a differentiated neuroscience company, rooted in innovation and driven by a commitment to addressing the unmet needs of patients living with neurological diseases. Net product revenue increased by $29.5 million, or 12.3%, for the three months ended September 30, 2026, and increased by $120.9 million, or 19.4%, for the nine months ended September 30, 2026, compared to the same periods in 2025. In June 2026, we submitted a New Drug Application (“NDA”) for Pitolisant GR to the FDA, which was subsequently accepted for full review with a target Prescription Drug User Fee Act (“PDUFA”) date of April 1, 2027. Open the document at this passage
Nov 4
Current report 8-K
WAKIX revenue reached $268.9 million as guidance held

Harmony Biosciences reported WAKIX net revenue of $268.9 million for the quarter ended September 30, 2026 and reiterated 2026 guidance of $1.0 billion to $1.04 billion. BP-205 preliminary results were favorable, and Peter Anastasiou will become CEO on January 1, 2027.

Financial results, Regulation FD disclosure
4 source passages
WAKIX net revenue for the quarter ended September 30, 2026, was $268.9 million, driven by strong patient demand: Based on our results for the first nine months of 2026, WAKIX remains on track to achieve full-year net revenue of $1.0 billion to $1.04 billion. The encouraging preliminary results from the MAD study with BP-205, following 14 days of repeated once-daily dosing, reinforce the favorable safety, tolerability and pharmacokinetic profile observed in the single-ascending dose (SAD) portion of the study. Peter Anastasiou, Senior Executive Vice President and Chief Operating Officer, will become President and Chief Executive Officer effective January 1, 2027, succeeding Jeffrey Dayno, MD, who will retire on December 31, 2026. Open the document at this passage
Oct 30
Current report 8-K/A Events of Oct 12
CEO succession terms include severance and equity awards

Harmony Biosciences Holdings, Inc. said Jeffrey M. Dayno will retire as CEO effective December 31, 2026, receive $770,000, and be succeeded by Peter Anastasiou effective January 1, 2027. Anastasiou’s salary will be $725,000, with equity awards of $1,750,000 and $750,000.

Director or officer change, or executive pay Read from the first part of this long document
5 source passages
On October 12, 2026, the Company announced that Jeffrey M. Dayno, M.D., as part of a leadership succession plan, will be retiring as the Company’s President and Chief Executive Officer and stepping down as a Class I director of the Company’s Board of Directors (the “Board”), in each case, effective as of December 31, 2026, at 11:59 p.m. Eastern Time (the “Resignation Effective Date”), and will serve as a non-executive advisor to the Company through January 2028. On October 12, 2026, the Company also announced that Peter Anastasiou, the Company’s current Senior Executive Vice President, Chief Operating Officer, has been appointed by the Board to serve as President and Chief Executive Officer of the Company and as a Class I director of the Company’s Board, each effective as of January 1, 2027, at 12:00 a.m. Eastern Time (the “Appointment Effective Date”) to fill the vacancy resulting from Dr. Dayno’s resignation. The Company shall pay to Executive an amount equal to $770,000, representing 12 months of Executive’s base salary as in effect on the Separation Date, payable pursuant to Section 3.03(a) of the Employment Agreement; Mr. Anastasiou’s annual base salary will be $725,000, effective as of the Appointment Effective Date. Within 30 days of the Appointment Effective Date, Mr. Anastasiou will be eligible to receive an option award and an award of restricted stock units with an aggregate grant date fair value of $1,750,000 and $750,000, respectively. Open the document at this passage
Oct 13
Current report 8-K Events of Oct 12
Director or officer change, or executive pay, Regulation FD disclosure

Harmony Biosciences Holdings, Inc. appointed Peter Anastasiou CEO and director effective January 1, 2027; Jeffrey M. Dayno, M.D., will retire and leave the board on December 31, 2026. Full-year 2026 WAKIX net revenue guidance remains $1.0 billion to $1.04 billion.

All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$989.36M
Trailing 12 months
Net income (TTM)
$178.60M
Trailing 12 months
Revenue growth YoY
+12.3%
Year over year
Operating margin
22.2%
Trailing 12 months
P / E (TTM)
10.9
Trailing earnings · reciprocal yield 9.1%
FCF yield
—
TTM · current market cap
Return on invested capital
37.4%
Trailing 12 months
Net cash
$622.03M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+1.6%
Year over year · more shares
Price change (1Y)
-2.9%
Trailing year
Short interest
11.3%
Latest settlement · 5.6 days to cover
View all 125 metrics

AI Brief

Q1 FY26 earnings call · May 7, 2026
Q1 FY26

TL;DR. Q1 2026 WAKIX net revenue rose 17% to $215.4 million, and management reiterated full-year 2026 net revenue guidance of $1.00 to $1.04 billion. Net income fell to $32.5 million ($0.55 per diluted share) because of $32 million in upfront amorphous-license charges, and the BP-205 Phase 1 PK data readout is expected in mid-2026.

Bullish
  • + Q1 WAKIX net product revenue grew 17% year over year to $215.4 million.
  • + Full-year 2026 WAKIX net revenue guidance of $1.00 to $1.04 billion was reiterated.
  • + BP-205 Phase 1 single-ascending-dose PK data readout is on track for mid-2026.
Bearish
  • − Net income fell to $32.5 million ($0.55 per diluted share) from $45.6 million ($0.78) a year earlier.
  • − Cost of product sold rose to 20.7% of net product revenue from 17.3%, driven by new Novitium license royalties.
  • − Higher-than-usual market access headwinds, including plan switching and premium increases, delayed some patient starts.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Sell Momentum Neutral Sentiment Neutral Fundamentals Excellent Quant / Vol High
Market backdrop VIX 25.5 · fear Equity put/call 0.71
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −4%
below
Price vs 50-day avg −14%
below
RSI (14) 34
neutral
MACD trend Negative
52-week position 40%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Neutral
1-month return −15%
trailing
6-month return +5%
trailing
YTD return −12%
this year
Relative strength +8%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $38 › 200d $35 — 50d above 200d
Institutional flow Accumulating
+11% holders QoQ · +66 funds added
Insider flow Distributing
Net -$3.1M over 90 days · 100% sells
Short interest Rising
11.35% of shares out · ▲ +23.1% MoM · 5.6 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
364 holders — near 3-yr high, broad support
Squeeze score 69
elevated · 0–100
Fundamentals
Excellent
Revenue growth +22%
Y/Y
Gross margin 77%
contracting
EPS growth +8%
Y/Y
Free cash flow $347.9M
Valuation P/E 10.9
below peers
Buyback $150.0M
remaining
Balance sheet $588.8M
net cash
Quant / Vol
risk profile
High
Volatility 41%
annualized · 1-yr
Max drawdown −34%
past year
ATR 4.6%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the 8-K filed Nov 4, 2026
WAKIX net revenue · full-year 2026 $1B – $1.04B
Previous outlook earlier release · from the Earnings Call filed Aug 4, 2026

Still-open targets the latest release did not restate under the same label.

Net revenue · full year 2026 $1B – $1.04B
Guided vs delivered · last 1 settled
Net revenue full year 2025
guided $845M – $865M
$868.45M Beat +1.6%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Sell
2 · 5 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−4% Neutral
Price vs 50-day avg
−14% Bearish
RSI (14)
34 Neutral
MACD trend
Negative Bearish
52-week position
40% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $38 › 200d $35 — 50d above 200d
Institutional flow Accumulating
+11% holders QoQ · +66 funds added
Insider flow Distributing
Net -$3.1M over 90 days · 100% sells
Short interest Rising
11.35% of shares out · ▲ +23.1% MoM · 5.6 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
364 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $27 Now $33 · 40% Range high $43
vs 200-day avg -4% vs 50-day avg -14%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Average patients 8,950 Q2 2026 —
Cash, cash equivalents and investments $962.5M as of June 30, 2026 —
Cost of product sold as a percentage of net product revenue 24.2% second quarter of 2026 —
Net patient adds 450 2Q26 —
number of units shipped 26.5% the three months ended June 30, 2026 filing —
WAKIX net product revenue growth 30% Q2 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
HRMY
Harmony Biosciences Holdings, Inc.
this stock
$1.94B -11.8% +21.5% 10.9 11.3%
VRTX
Vertex Pharmaceuticals Inc
$135.44B +17.8% +46.2% 34.4 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$99.08B +24.1% +20.8% 21.2 2.1%
MRNA
Moderna, Inc.
$83.68B +601.3% +4.3% — 8.2%
CSLLY
Csl Ltd
$64.25B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
364
% held
96.7%
Net QoQ
+2.6M sh
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
344
View
Short & Settlement
Short Interest Rising
Shares short
6.7M
Days to cover
5.6d
Change
+1.3M sh
View
Short Volume
Short vol %
46%
As of
Nov 17, 2026
Short Total
View
Fails to Deliver
FTD shares
1.7K
Value
$65.1K
As of
Oct 29, 2026
View
Off-Exchange
Off-exchange %
43.1%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$3.1M
Buyers / Sellers
0 / 1
Buyers Sellers
View
Financials
Financials
Revenue (FY)
$868.5M
Net income (FY)
$158.7M
EPS diluted
$2.71
View
Buybacks
Remaining
$150.0M
View
Filings
SEC Filings
Latest
8-K
Filed
Nov 4, 2026
This year
20

Harmony Biosciences reported WAKIX net revenue of $268.9 million for the quarter ended September 30, 2026 and reiterated 2026 guidance of $1.0 billion to $1.04 billion. BP-205 preliminary results were favorable, and Peter Anastasiou will become CEO on January 1, 2027.

View
Proposed Sales
Value
$1.5M
Shares
35.9K
Filed
Sep 18, 2026
View
Earnings & Events
Webcasts
Last webcast
Nov 4, 2026
View
Investor Relations
Latest news
Harmony Biosciences to Report Thi…
Published
Oct 20, 2026
View

Performance

5D 20D 120D MTD YTD
HRMY -1.6% -14.7% +4.8% -14.8% -11.8%
SPY -2.3% -4.8% -2.9% -3.1% +7.4%
vs SPY +0.7% -9.9% +7.8% -11.8% -19.2%

Capital returns

Buyback program · as of Sep 30, 2026
Authorized
—
Spent (derived)
—
Remaining
$150.00M

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1802665 CUSIP 413197104 13F (30d) 362 filings 343 filers Visit website Investor relations